Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapacitabine in previously treated NSCLC
NCT00885963Phase 2Terminated
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Dec 2008
- Primary completion
- Aug 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapacitabine in non-small cell lung cancer (NSCLC), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Rate of Response and Stable Disease. Started Dec 2008; status: terminated.
02
Drugs
sapacitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00885963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885963.